Rebound activity after fingolimod cessation: A case – control study-Reference-Cited by-同舟云学术

Rebound activity after fingolimod cessation: A case – control study

Published:2022-01 Issue: Volume:57 Page:103329
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Barboza Andres,Gaitán María Inés,Alonso Ricardo,Ysrraelit María Célica,Luetic Geraldine,Liwacki Susana,Patrucco Liliana,Halfon Mario Javier,Burgos Marcos,Mainella Carolina,Pierdabuena Raul,Recchia Luciano,Steinberg Judith,Tkachuk Veronica Analia,Zanga Gisela,Carra Adriana,Chertcoff Aníbal,Fernandez Liguori Nora,Lazaro Luciana,Menichini Maria Laura,Miguez Jimena,Orzuza Gabriela,Palavecino Alfredo,Pappolla Agustin,Pigretti Santiago,Pita Cacilia,Ruiz Emiliano,Silva Berenice,Zentil Guillermo

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference19 articles.

1. F.ingolimod Rebound: a Review of the Clinical Experience and Management Considerations;Barry;Neurol. Ther.,2019

2. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients;Sorensen;J. Neurol.,2014

3. What to expect after natalizumab cessation in a real-life setting;Salhofer-Polanyi;Acta Neurol. Scand.,2014

4. Rebound exacerbation multiple sclerosisfollowing cessation of oral treatment;Beran;Mult. Scler. Relat. Disord.,2013

5. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment;Havla;Arch. Neurol.,2012

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Frequency and risk factors of rebound after fingolimod discontinuation – A retrospective study;Multiple Sclerosis and Related Disorders;2024-01

2. Risk of T2 lesions when discontinuing fingolimod: a nationwide predictive and comparative study;Brain Communications;2023-12-28

3. Radiological abnormalities in progressive multifocal leukoencephalopathy: Identifying typical and atypical imaging patterns for early diagnosis and differential considerations;Multiple Sclerosis and Related Disorders;2023-09

4. Real-World Clinical and Economic Outcomes Among Persons With Multiple Sclerosis Initiating First- Versus Second- or Later-Line Treatment With Ocrelizumab;Neurology and Therapy;2023-07-17

5. An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis;Expert Opinion on Pharmacotherapy;2023-03-04